Buspirone Explained

Watchedfields:changed
Verifiedrevid:459522704
Width:250
Pronounce:
Tradename:Buspar
Dailymedid:Buspirone
Pregnancy Au:B1
Routes Of Administration:By mouth
Atc Prefix:N05
Atc Suffix:BE01
Legal Au:S4
Legal Br:C1
Legal Br Comment:[1]
Legal Ca:Rx-only
Legal Uk:POM
Legal Us:Rx-only
Bioavailability:3.9%[2]
Protein Bound:86–95%[3]
Metabolism:Liver (via CYP3A4)[4]
Metabolites:5-OH-Buspirone; 6-OH-Buspirone; 8-OH-Buspirone;
Elimination Half-Life:2.5 hours[5]
Excretion:Urine

29–63%
Feces: 18–38%

Index2 Label:as HCl
Cas Number:36505-84-7
Cas Number2:33386-08-2
Pubchem:2477
Iuphar Ligand:36
Drugbank:DB00490
Chemspiderid:2383
Unii:TK65WKS8HL
Kegg:D07593
Chebi:3223
Chembl:49
Synonyms:MJ 9022-1
Iupac Name:8--8-azaspiro[4.5]decane-7,9-dione
C:21
H:31
N:5
O:2
Smiles:O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1
Stdinchi:1S/C21H31N5O2/c27-18-16-21(6-1-2-7-21)17-19(28)26(18)11-4-3-10-24-12-14-25(15-13-24)20-22-8-5-9-23-20/h5,8-9H,1-4,6-7,10-17H2
Stdinchikey:QWCRAEMEVRGPNT-UHFFFAOYSA-N

Buspirone, sold under the brand name Buspar, among others, is an anxiolytic, a medication primarily used to treat anxiety disorders, particularly generalized anxiety disorder.[6] It is a serotonin 5-HT1A receptor agonist, increasing action at serotonin receptors in the brain. It is taken orally, and takes two to six weeks to be fully effective.[6]

Common side effects of buspirone include nausea, headaches, dizziness, and difficulty concentrating.[6] [7] Serious side effects may include movement disorders, serotonin syndrome, and seizures.[7] Its use in pregnancy appears to be safe but has not been well studied, and use during breastfeeding has not been well studied.[7] [8]

Buspirone was developed in 1968 and approved for medical use in the United States in 1986.[6] [9] It is available as a generic medication.[7] In 2021, it was the 53rd most-commonly prescribed medication in the United States, with more than 12million prescriptions.[10] [11]

Medical uses

Anxiety

Buspirone is used for the short-term and long-term treatment of anxiety disorders or symptoms of anxiety.[12] [13] [14] [15] [16] It is generally preferred over benzodiazepines because it does not activate the receptors that make drugs like alprazolam addictive.[9]

Buspirone has no immediate anxiolytic effects, and hence has a delayed onset of action; its full clinical effectiveness may require 2–4 weeks to manifest itself.[17] The drug has been shown to be similarly effective in the treatment of generalized anxiety disorder (GAD) to benzodiazepines including diazepam, alprazolam, lorazepam, and clorazepate. Buspirone is not known to be effective in the treatment of other anxiety disorders besides GAD.[18]

Other uses

Sexual dysfunction

There is some evidence that buspirone on its own may be useful in the treatment of hypoactive sexual desire disorder (HSDD) in women.[19] Buspirone may also be effective in treating antidepressant-induced sexual dysfunction.[9] [20] [21]

Miscellaneous

Buspirone is not effective as a treatment for benzodiazepine withdrawal, barbiturate withdrawal, or alcohol withdrawal/delirium tremens.[22]

SSRI and SNRI antidepressants such as paroxetine and venlafaxine may cause jaw pain/jaw spasm reversible syndrome (although it is not common), and buspirone appears to be successful in treating bruxism on SSRI/SNRI-induced jaw clenching.[23] [24]

Contraindications

Buspirone has these contraindications:[25] [26]

Side effects

See main article: List of side effects of buspirone.

Known side effects associated with buspirone include dizziness, headaches, nausea, tinnitus, and paresthesia. Buspirone is relatively well tolerated, and is not associated with sedation, cognitive and psychomotor impairment, muscle relaxation, physical dependence, or anticonvulsant effects. In addition, buspirone does not produce euphoria and is not a drug of abuse.[13]

Overdose

Buspirone appears to be relatively benign in cases of single-drug overdose, although no definitive data on this subject appear to be available.[27] In one clinical trial, buspirone was administered to healthy male volunteers at a dosage of 375 mg/day, and produced side effects including nausea, vomiting, dizziness, drowsiness, miosis, and gastric distress.[12] [13] [15] In early clinical trials, buspirone was given at dosages even as high as 2,400 mg/day, with akathisia, tremor, and muscle rigidity observed.[28] Deliberate overdoses with 250 mg and up to 300 mg buspirone have resulted in drowsiness in about 50% of individuals. One death has been reported in a co-ingestion of 450 mg buspirone with alprazolam, diltiazem, alcohol, cocaine.

Interactions

Buspirone has been shown in vitro to be metabolized by the enzyme CYP3A4. This finding is consistent with the in vivo interactions observed between buspirone and these inhibitors or inducers of cytochrome P450 3A4 (CYP3A4), among others:[25]

Moderately increase plasma levels of buspirone.[30]

Elevated blood pressure has been reported when buspirone has been administered to patients taking monoamine oxidase inhibitors (MAOIs).[25]

Pharmacology

Pharmacodynamics

Buspirone[31]
Site Ki (nM)ActionSpecies Ref
5-HT1A3.98–214
21 (median)		AgonistHuman [32]
>100,000Agonist ? [33] Rat [34]
22,000–42,700Agonist ? Human [35] [36]
5-HT2C1,100–6,026Antagonist ? Rat/pig
5-HT7375–381
840		Antagonist ? Rat
Human 		[37] [38]
[39]
1,000AntagonistRat
6,000AntagonistRat [40]
  α2A7.3 AntagonistHuman
8,800AntagonistRat
33,000AntagonistRat
D2484
240		AntagonistHuman
Rat 		[41]
D398AntagonistHuman
D429AntagonistHuman
38,000?Rat
>100,000-Rat
Values are Ki (nM). The smaller the value, the more strongly the drug binds to the site.

Buspirone acts as an agonist of the serotonin 5-HT1A receptor with high affinity.[2] It is a partial agonist of both presynaptic 5-HT1A receptors, which are inhibitory autoreceptors, and postsynaptic 5-HT1A receptors. It is thought that the main effects of buspirone are mediated via its interaction with the presynaptic 5-HT1A receptor, thus reducing the firing of serotonin-producing neurons. Buspirone also seems to have lower affinities for the serotonin 5-HT2A, 5-HT2B, 5-HT2C, 5-HT6, 5-HT7 receptors probably as an antagonist.

In addition to binding to serotonin receptors, buspirone is an antagonist of the dopamine D2 receptor with weak affinity.[2] It preferentially blocks inhibitory presynaptic D2 autoreceptors, and antagonizes postsynaptic D2 receptors only at higher doses. In accordance, buspirone has been found to increase dopaminergic neurotransmission in the nigrostriatal pathway at low doses, whereas at higher doses, postsynaptic D2 receptors are blocked and antidopaminergic effects such as hypoactivity and reduced stereotypy, though notably not catalepsy, are observed in animals. Buspirone has also been found to bind with much higher affinity to the dopamine D3 and D4 receptors, where it is similarly an antagonist.

A major metabolite of buspirone, 1-(2-pyrimidinyl)piperazine (1-PP), occurs at higher circulating levels than buspirone itself and is known to act as a potent α2-adrenergic receptor antagonist.[42] [43] This metabolite may be responsible for the increased noradrenergic and dopaminergic activity observed with buspirone in animals.[44] Buspirone also has very weak and probably clinically unimportant affinity for the α1-adrenergic receptor.[45] However, buspirone has been reported to have shown "significant and selective intrinsic efficacy" at the α1-adrenergic receptor expressed in a "tissue- and species-dependent manner".

Unlike benzodiazepines, buspirone does not interact with the GABAA receptor complex.[46]

Pharmacokinetics

Buspirone has a low oral bioavailability of 3.9% relative to intravenous injection due to extensive first-pass metabolism. The time to peak plasma levels following ingestion is 0.9 to 1.5 hours. It is reported to have an elimination half-life of 2.8 hours, although a review of 14 studies found that the mean terminal half-life ranged between 2 and 11 hours, and one study even reported a terminal half-life of 33 hours.[47] Buspirone is metabolized primarily by CYP3A4, and prominent drug interactions with inhibitors and inducers of this enzyme have been observed. Major metabolites of buspirone include 5-hydroxybuspirone, 6-hydroxybuspirone, 8-hydroxybuspirone, and 1-PP.[48] [49] 6-Hydroxybuspirone has been identified as the predominant hepatic metabolite of buspirone, with plasma levels that are 40-fold greater than those of buspirone after oral administration of buspirone to humans.[50] The metabolite is a high-affinity partial agonist of the 5-HT1A receptor (Ki=25 nM) similarly to buspirone, and has demonstrated occupancy of the 5-HT1A receptor in vivo. As such, it is likely to play an important role in the therapeutic effects of buspirone. 1-PP has also been found to circulate at higher levels than those of buspirone itself and may similarly play a significant role in the clinical effects of buspirone.

Chemistry

Buspirone is a member of the azapirone chemical class, and consists of azaspirodecanedione and pyrimidinylpiperazine components linked together by a butyl chain.

Analogues

Structural analogues of buspirone include other azapirones like gepirone, ipsapirone, perospirone, and tandospirone.[51]

A number of analogues are recorded.[52]

Synthesis

A number of methods of synthesis have also been reported.[53] [54] [55] One method begins with alkylation of 1-(2-pyrimidyl)piperazine (1) with 3-chloro-1-cyanopropane (4-chlorobutyronitrile) (2) to give (3). Next, reduction of the nitrile group is performed either by catalytic hydrogenation or with lithium aluminium hydride (LAH) giving (4). The primary amine is then reacted with 3,3-tetramethyleneglutaric anhydride (5) in order to yield buspirone (6).[56] [57] [58] [59] [60]

History

Buspirone was first synthesized by a team at Mead Johnson in 1968 but was not patented until 1980.[61] [56] [62] It was initially developed as an antipsychotic acting on the D2 receptor but was found to be ineffective in the treatment of psychosis; it was then used as an anxiolytic instead. In 1986, Bristol-Myers Squibb gained FDA approval for buspirone in the treatment of GAD.[63] The patent expired in 2001, and buspirone is now available as a generic drug.

Society and culture

Generic names

Buspirone is the,,, and of buspirone, while buspirone hydrochloride is its,, and .[64] [65] [66] [67]

Brand names

Buspirone was primarily sold under the brand name Buspar. Buspar is currently listed as discontinued by the US Food and Drug Administration.[68] In 2010, in response to a citizen petition, the US FDA determined that Buspar was not withdrawn from sale for reasons of safety or effectiveness.[69]

Notes and References

  1. Web site: Anvisa . Brazilian Health Regulatory Agency . 31 March 2023 . RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial . Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control . live . https://web.archive.org/web/20230803143925/https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 . 3 August 2023 . 16 August 2023 . . pt-BR . 4 April 2023.
  2. Loane C, Politis M . Buspirone: what is it all about? . Brain Research . 1461 . 111–118 . June 2012 . 22608068 . 10.1016/j.brainres.2012.04.032 . 11734819 .
  3. Web site: buspirone (Rx) - BuSpar, Buspirex, more... Medscape Reference. WebMD. 14 November 2013.
  4. Zhu M, Zhao W, Jimenez H, Zhang D, Yeola S, Dai R, Vachharajani N, Mitroka J . Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes . Drug Metabolism and Disposition . 33 . 4 . 500–507 . April 2005 . 15640381 . 10.1124/dmd.104.000836 . 10142905 .
  5. Mahmood I, Sahajwalla C . Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug . Clinical Pharmacokinetics . 36 . 4 . 277–287 . April 1999 . 10320950 . 10.2165/00003088-199936040-00003 . 1102318 .
  6. Web site: Buspirone Hydrochloride Monograph for Professionals . Drugs.com.
  7. Book: British national formulary : BNF 76 . 2018 . Pharmaceutical Press . 9780857113382 . 338 . 76.
  8. Web site: Buspirone Pregnancy and Breastfeeding Warnings . Drugs.com.
  9. Buspirone . StatPearls . January 2018 . 30285372 . Wilson TK, Tripp J .
  10. Web site: The Top 300 of 2021 . ClinCalc . 14 January 2024 . 15 January 2024 . https://web.archive.org/web/20240115223848/https://clincalc.com/DrugStats/Top300Drugs.aspx . live .
  11. Web site: Buspirone - Drug Usage Statistics . ClinCalc . 14 January 2024.
  12. Web site: BUSPIRONE HCL (buspirone hydrochloride) tablet [Watson Laboratories, Inc.]]. DailyMed. Watson Laboratories, Inc.. July 2013. 14 November 2013.
  13. Web site: BUSPAR® (buspirone hydrochloride) Tablets 5 mg & 10 mg PRODUCT INFORMATION. TGA eBusiness Services. Aspen Pharma Pty Ltd. January 2010. 14 November 2013. PDF.
  14. Book: Australian Medicines Handbook . 2013 . The Australian Medicines Handbook Unit Trust . 978-0-9805790-9-3 . 2013 . Adelaide . Rossi S .
  15. Web site: Buspirone 10mg Tablets . electronic Medicines Compendium . Actavis UK Ltd . 10 September 2012 . 14 November 2013 . 13 November 2013. https://web.archive.org/web/20131113191142/http://www.medicines.org.uk/emc/medicine/23859/SPC/Buspirone+10mg+Tablets/. dead.
  16. Book: Joint Formulary Committee . British National Formulary (BNF) . Pharmaceutical Press . 224 .
  17. Book: Sadock BJ, Sadock VA, Ruiz P . Kaplan and Sadock's Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry . 22 September 2014. Wolters Kluwer Health . 978-1-4698-8375-5. 3211–.
  18. Howland RH . Buspirone: Back to the Future . Journal of Psychosocial Nursing and Mental Health Services . 53 . 11 . 21–24 . November 2015 . 26535760 . 10.3928/02793695-20151022-01 .
  19. Goldstein I, Kim NN, Clayton AH, DeRogatis LR, Giraldi A, Parish SJ, Pfaus J, Simon JA, Kingsberg SA, Meston C, Stahl SM, Wallen K, Worsley R . Hypoactive Sexual Desire Disorder: International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel Review . Mayo Clinic Proceedings . 92 . 1 . 114–128 . January 2017 . 27916394 . 10.1016/j.mayocp.2016.09.018 . free .
  20. Trinchieri M, Trinchieri M, Perletti G, Magri V, Stamatiou K, Cai T, Montanari E, Trinchieri A . Erectile and Ejaculatory Dysfunction Associated with Use of Psychotropic Drugs: A Systematic Review . The Journal of Sexual Medicine . 18 . 8 . 1354–1363 . August 2021 . 34247952 . 10.1016/j.jsxm.2021.05.016 . 235798526 . Buspirone, a non-benzodiazepine anxiolytic, have even demonstrated enhancement of sexual function in certain individuals. For this reason, they have been proposed as augmentation agents (antidotes) or substitution agents in patients with emerging sexual dysfunction after treatment with antidepressants..
  21. Montejo AL, Prieto N, de Alarcón R, Casado-Espada N, de la Iglesia J, Montejo L . Management Strategies for Antidepressant-Related Sexual Dysfunction: A Clinical Approach . Journal of Clinical Medicine . 8 . 10 . October 2019 . 1640 . 31591339 . 6832699 . 10.3390/jcm8101640 . free .
  22. Sontheimer DL, Ables AZ . Is imipramine or buspirone treatment effective in patients wishing to discontinue long-term benzodiazepine use? . The Journal of Family Practice . 50 . 3 . 203 . March 2001 . 11252203 .
  23. Garrett AR, Hawley JS . SSRI-associated bruxism: A systematic review of published case reports . Neurology. Clinical Practice . 8 . 2 . 135–141 . April 2018 . 29708207 . 5914744 . 10.1212/CPJ.0000000000000433 .
  24. Prisco V, Iannaccone T, Di Grezia G . 1 April 2017 . Use of buspirone in selective serotonin reuptake inhibitor-induced sleep bruxism. European Psychiatry. Abstract of the 25th European Congress of Psychiatry. 41 . S855 . 10.1016/j.eurpsy.2017.01.1701 . 148816505 .
  25. Web site: Buspirone monograph . Drugs.com . 27 August 2011.
  26. Book: Geddes J, Gelder MG, Mayou R . Psychiatry . Oxford University Press . Oxford [Oxfordshire] . 2005 . 237 . 978-0-19-852863-0 .
  27. Fulton B, Brogden RN . Buspirone. CNS Drugs. 7. 1. 1997. 68–88. 1172-7047. 10.2165/00023210-199707010-00007. 57668523 .
  28. Book: Dart RC . Medical Toxicology . 2004 . Lippincott Williams & Wilkins . 978-0-7817-2845-4 . 886– .
  29. Lilja JJ, Kivistö KT, Backman JT, Lamberg TS, Neuvonen PJ . Grapefruit juice substantially increases plasma concentrations of buspirone . Clinical Pharmacology and Therapeutics . 64 . 6 . 655–660 . December 1998 . 9871430 . 10.1016/S0009-9236(98)90056-X . 22009095 .
  30. Lamberg TS, Kivistö KT, Laitila J, Mårtensson K, Neuvonen PJ . The effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of buspirone . European Journal of Clinical Pharmacology . 54 . 9–10 . 761–766 . 1998 . 9923581 . 10.1007/s002280050548 . 21939719 .
  31. Web site: PDSP Ki Database . Psychoactive Drug Screening Program (PDSP). Bryan Roth . Roth BL, Driscol J . University of North Carolina at Chapel Hill and the United States National Institute of Mental Health . 14 August 2017 .
  32. Boess FG, Martin IL . Molecular biology of 5-HT receptors . Neuropharmacology . 33 . 3–4 . 275–317 . 1994 . 7984267 . 10.1016/0028-3908(94)90059-0 . 35553281 .
  33. Sato H, Skelin I, Diksic M . Chronic buspirone treatment decreases 5-HT1B receptor densities and the serotonin transporter but increases the density of 5-HT2A receptors in the bulbectomized rat model of depression: an autoradiographic study . Brain Research . 1345 . 28–44 . July 2010 . 20501324 . 10.1016/j.brainres.2010.05.054 . 22979155 .
  34. Hamik A, Oksenberg D, Fischette C, Peroutka SJ . Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites . Biological Psychiatry . 28 . 2 . 99–109 . July 1990 . 1974152 . 10.1016/0006-3223(90)90627-e . 25608914 . free .
  35. Peroutka SJ, Switzer JA, Hamik A . Identification of 5-hydroxytryptamine1D binding sites in human brain membranes . Synapse . 3 . 1 . 61–66 . 1989 . 2521959 . 10.1002/syn.890030109 . 23503235 .
  36. Waeber C, Schoeffter P, Palacios JM, Hoyer D . Molecular pharmacology of 5-HT1D recognition sites: radioligand binding studies in human, pig and calf brain membranes . Naunyn-Schmiedeberg's Archives of Pharmacology . 337 . 6 . 595–601 . June 1988 . 2975354 . 10.1007/bf00175783 . 21344978 .
  37. Lovenberg TW, Baron BM, de Lecea L, Miller JD, Prosser RA, Rea MA, Foye PE, Racke M, Slone AL, Siegel BW . A novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms . Neuron . 11 . 3 . 449–458 . September 1993 . 8398139 . 10.1016/0896-6273(93)90149-l . 28729004 .
  38. Ruat M, Traiffort E, Leurs R, Tardivel-Lacombe J, Diaz J, Arrang JM, Schwartz JC . Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation . Proceedings of the National Academy of Sciences of the United States of America . 90 . 18 . 8547–8551 . September 1993 . 8397408 . 47394 . 10.1073/pnas.90.18.8547 . free . 1993PNAS...90.8547R .
  39. Perry CK, Casey AB, Felsing DE, Vemula R, Zaka M, Herrington NB, Cui M, Kellogg GE, Canal CE, Booth RG . Synthesis of novel 5-substituted-2-aminotetralin analogs: 5-HT1A and 5-HT7 G protein-coupled receptor affinity, 3D-QSAR and molecular modeling . Bioorganic & Medicinal Chemistry . 28 . 3 . 115262 . February 2020 . 31882369 . 10.1016/j.bmc.2019.115262 . 209498915 . free .
  40. Blier P, Curet O, Chaput Y, de Montigny C . Tandospirone and its metabolite, 1-(2-pyrimidinyl)-piperazine--II. Effects of acute administration of 1-PP and long-term administration of tandospirone on noradrenergic neurotransmission . Neuropharmacology . 30 . 7 . 691–701 . July 1991 . 1681447 . 10.1016/0028-3908(91)90176-c . 44297577 .
  41. Bergman J, Roof RA, Furman CA, Conroy JL, Mello NK, Sibley DR, Skolnick P . Modification of cocaine self-administration by buspirone (buspar®): potential involvement of D3 and D4 dopamine receptors . The International Journal of Neuropsychopharmacology . 16 . 2 . 445–458 . March 2013 . 22827916 . 5100812 . 10.1017/S1461145712000661 .
  42. Tunnicliff G . Molecular basis of buspirone's anxiolytic action . Pharmacology & Toxicology . 69 . 3 . 149–156 . September 1991 . 1796057 . 10.1111/j.1600-0773.1991.tb01289.x .
  43. Zuideveld KP, Rusiç-Pavletiç J, Maas HJ, Peletier LA, Van der Graaf PH, Danhof M . Pharmacokinetic-pharmacodynamic modeling of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in rats . The Journal of Pharmacology and Experimental Therapeutics . 303 . 3 . 1130–1137 . December 2002 . 12438536 . 10.1124/jpet.102.036798 . 14139919 .
  44. Fava M . 2007 . The combination of buspirone and bupropion in the treatment of depression . Psychotherapy and Psychosomatics . 76 . 5 . 311–312 . 10.1159/000104708 . 17700052 . 46284917.
  45. Book: Stern TA, Fava M, Wilens TE, Rosenbaum JF . Massachusetts General Hospital Psychopharmacology and Neurotherapeutics E-Book . 27 April 2015 . Elsevier Health Sciences . 978-0-323-41323-7 . 29–.
  46. Book: Nutt DJ, Ballenger JC . Anxiety Disorders. 15 April 2008. John Wiley & Sons. 978-0-470-98683-7. 395–.
  47. Gammans RE, Mayol RF, LaBudde JA . Metabolism and disposition of buspirone . The American Journal of Medicine . 80 . 3B . 41–51 . March 1986 . 3515929 . 10.1016/0002-9343(86)90331-1 .
  48. Zhu Y, Chen G, Zhang K, Chen C, Chen W, Zhu M, Jiang H . High-Throughput Metabolic Soft-Spot Identification in Liver Microsomes by LC/UV/MS: Application of a Single Variable Incubation Time Approach . Molecules . 27 . 22 . 8058 . November 2022 . 36432161 . 9693510 . 10.3390/molecules27228058 . free .
  49. Wong H, Dockens RC, Pajor L, Yeola S, Grace JE, Stark AD, Taub RA, Yocca FD, Zaczek RC, Li YW . 6-Hydroxybuspirone is a major active metabolite of buspirone: assessment of pharmacokinetics and 5-hydroxytryptamine1A receptor occupancy in rats . Drug Metabolism and Disposition . 35 . 8 . 1387–1392 . August 2007 . 17494642 . 10.1124/dmd.107.015768 . 25558546 .
  50. Book: Schatzberg AF, Nemeroff CB . The American Psychiatric Publishing Textbook of Psychopharmacology . 2009 . American Psychiatric Pub . 978-1-58562-309-9 . 490–.
  51. Taylor DP, Moon SL . Buspirone and related compounds as alternative anxiolytics . Neuropeptides . 19 . Suppl . 15–19 . July 1991 . 1679210 . 10.1016/0143-4179(91)90078-w . 13730683 .
  52. Yevich JP, Temple DL, New JS, Taylor DP, Riblet LA . Buspirone analogues. 1. Structure-activity relationships in a series of N-aryl- and heteroarylpiperazine derivatives . Journal of Medicinal Chemistry . 26 . 2 . 194–203 . February 1983 . 6131130 . 10.1021/jm00356a014 . 28619843 .
  53. Cybulski J, Chilmonczyk Z, Szelejewski W, Wojtasiewicz K, Wróbel JT . 1992 . An Efficient Synthesis of Buspirone and its Analogues. . Archiv der Pharmazie . 325 . 5 . 313–315 . 10.1002/ardp.19923250513 . 83676454 .
  54. Kuo DL . 1993 . Pd(0)-catalysed Synthesis of Buspirone and Gepirone. . Heterocycles . 36 . 7 . 1463–1469 . 10.3987/COM-93-6357 .
  55. Mou J, Zong ZM, Wei XY . Facile Synthesis of Anxiolytic Buspirone . August 2008 . Organic Preparations and Procedures International . 40 . 4 . 391–394 . 10.1080/00304940809458099 . 95124245 . 0030-4948 . 1945-5453.
  56. Allen LE, Ferguson HC, Kissel JW . Psychosedative agents. 2. 8-(4-Substituted 1-piperazinylalkyl)-8-azaspiro(4.5)decane-7,9-diones . Journal of Medicinal Chemistry . 15 . 5 . 477–479 . May 1972 . 5035267 . 10.1021/jm00275a009 .
  57. DE2057845 idem Y Wu, J Rayburn, (1973 to Mead Johnson).
  58. Wu YH, Rayburn JW . US . 3907801 . 1975 . Mead Johnson.
  59. Wu YH, Rayburn JW . US . 3976776 . 1976 . Mead Johnson.
  60. Behme RJ, Kensler TT, Mikolasek DG . US . 4810789 . 1989 . Bristol Myers.
  61. US . 4182763 . Buspirone anti-anxiety method . 1980-01-08 . Casten GP, McKinney GR, Newton RE, Tompkins EC, Weikel Jr JH . Mead Johnson & Co.. Bristol-Meyers Co..
  62. US . 3907801. 1975-09-23 . N-[(4-pyridyl-piperazino)-alkyl]-azaspiroalkanediones . Mead_Johnson. Hua WY, Warren RJ .
  63. Web site: United States Federal Drug Administration . 9 September 1986 . Approval Type-1 New Molecular Entry. .
  64. Book: Elks J . The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies . 14 November 2014 . Springer . 978-1-4757-2085-3 . 192–.
  65. Book: Index Nominum 2000: International Drug Directory . January 2000. Taylor & Francis . 978-3-88763-075-1. 149–.
  66. Book: Morton IK, Hall JM . Concise Dictionary of Pharmacological Agents: Properties and Synonyms . 6 December 2012. Springer Science & Business Media. 978-94-011-4439-1. 57–.
  67. Web site: Buspirone . Drugs.com .
  68. Web site: Drugs@FDA: FDA Approved Drug Products. Food and Drug Administration.
  69. Web site: Determination That BUSPAR (Buspirone Hydrochloride) Tablets, 10 Milligrams, 15 Milligrams, and 30 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness. 19 October 2010. Federal Register. 20 September 2019.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Buspirone".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.